# Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

> **NCT00803569** · PHASE1 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 13 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine
- **BIOLOGICAL:** Sargramostim

## Key facts

- **NCT ID:** NCT00803569
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-14
- **Primary completion:** 2011-01-24
- **Final completion:** 2011-01-24
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-10-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00803569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00803569, "Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00803569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*